Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.
about
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatmentEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsOverview and management of cardiac adverse events associated with tyrosine kinase inhibitorsHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaThe Role of CC-Chemokines in the Regulation of AngiogenesisWinning a Won Game: Caffeine Panacea for Obesity SyndemicThe therapeutic effect of bevacizumab on plaque neovascularization in a rabbit model of atherosclerosis during contrast-enhanced ultrasonography.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeuticsSorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case DiscussionRapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.Six-minute walk test improved forearm skin blood flow in Tunisian obese women.Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Preserved capillary density of dorsal finger skin in treated hypertensive patients with or without type 2 diabetes.Common secondary causes of resistant hypertension and rational for treatmentSuppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.The therapeuatic effect of Endostar on soft carotid plaque neovascularization in patients with non-small cell lung cancer.Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trialCardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a reviewInsight into 144 patients with ocular vascular events during VEGF antagonist injectionsThe current state of targeted agents in rectal cancer.Role of eNOS- and NOX-containing microparticles in endothelial dysfunction in patients with obesity.Management of antiangiogenic therapy-induced hypertension.Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and CilengitideTherapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertensionCardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational studyImmune cells control skin lymphatic electrolyte homeostasis and blood pressureEvaluation of hypertension as a marker of bevacizumab efficacyMechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancerVEGF inhibition, hypertension, and renal toxicityManagement of hypertension in angiogenesis inhibitor-treated patients.Angiogenesis and hypertension: an update.Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
P2860
Q24657761-ACACC7F3-CAB8-4672-A11D-E93732830784Q26786618-B894A57C-EF26-4BCD-A182-0F8D8B7CB5B7Q26865766-A2D799B8-AC83-43C6-A771-296D749196FAQ28066747-E33CCD6A-0B9E-4821-8178-4776F741E742Q28077024-9258A73F-8121-4D91-8B0F-A2F672A71424Q29540785-893051CD-607F-4BD5-9F8C-950B4929AF7AQ30377223-84B2F9A1-879F-4DCF-9554-DD8E5B703F81Q30417015-4D3190BC-A86F-4361-8C6E-929C798A9F86Q30587082-DF48F1DD-881A-4BEA-91D6-ED0A6646B0FFQ33432776-D81BC83B-5A48-4720-8A23-9268C0C999C0Q33659820-9F4BC3C3-E665-4AF5-8FA4-016E2E4E5C8DQ33684042-BC6058D1-8BEB-4A8F-8673-D7BE9AD1B424Q33710753-965848F0-2AB5-4590-9F07-D72C41504227Q33828690-20F649F8-18DE-48C0-9D80-EB896FF1D865Q33947901-DE5FF5A9-B1D4-4540-82CC-8C5694856DC6Q34245458-CF3D974C-20EE-4B63-BD04-39B3CBF92EE3Q34266335-D05E5A1B-CA6F-4BAE-A696-5FCE2A73C86EQ34669789-9E4A73A8-AC61-4A9B-8C19-6590DF90FADEQ34803030-25386F5A-5713-4FD2-A6F0-A4B4303899ACQ35144007-3311971E-1B1E-4236-B496-DB9456793BA7Q35160832-C15455C4-F4BC-4E41-9656-49A9AE5845CBQ35187848-E3FF6FF0-8CD6-4D72-99F3-2AA1E2624810Q35346619-CDFFE2F3-6094-4F2B-AD7D-20FD431A0B89Q35584543-163BB8D1-21FF-4460-B177-A0160226C0F1Q35822200-314D5BA2-ADCE-44D5-BE6E-82329BEDC4C9Q35996651-DC4E79E5-A94F-4EE7-B875-6BB80B5FF298Q36003956-00372D22-A947-4EB8-9612-BE2CD045698EQ36170252-CA45A6E8-7AE8-45C8-A25F-439EC8CBA21DQ36368035-42A76B89-DC47-4C02-945F-41B5BA1F313CQ36678295-08756A41-5AF8-4C82-8C12-9F681D784338Q36751861-3ABDC461-346A-4F99-A959-28D13AADA012Q36858624-34B4BB3F-3345-4CD5-9060-A673DC3CC83FQ36966854-AD8BE4A0-E115-43E4-B21E-4E6295B33E03Q36991546-BABAE7C1-031B-4EC1-B6D8-4FDAEBCE58E2Q37038711-CF748C4A-D1FC-47B5-BEAC-CA2EE1C8CE37Q37094898-3443B04F-E90D-4595-95A4-101BB11ADD6AQ37103555-19E1EC36-81D7-454A-BA09-700B260984C9Q37371312-F4E1DB22-9598-4AF9-B3AF-B26CD3EE9814Q37579043-C624B996-E4AB-413E-9CAA-09C67DF0CD3AQ37688711-27034F1D-44D5-4331-90C5-4036592095A0
P2860
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Blood pressure rise following ...... ial role for microcirculation.
@ast
Blood pressure rise following ...... ial role for microcirculation.
@en
Blood pressure rise following ...... ial role for microcirculation.
@nl
type
label
Blood pressure rise following ...... ial role for microcirculation.
@ast
Blood pressure rise following ...... ial role for microcirculation.
@en
Blood pressure rise following ...... ial role for microcirculation.
@nl
prefLabel
Blood pressure rise following ...... ial role for microcirculation.
@ast
Blood pressure rise following ...... ial role for microcirculation.
@en
Blood pressure rise following ...... ial role for microcirculation.
@nl
P2093
P356
P1433
P1476
Blood pressure rise following ...... ial role for microcirculation.
@en
P2093
P304
P356
10.1093/ANNONC/MDM550
P577
2007-12-04T00:00:00Z